Hypertension - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hypertension - Pipeline Review, H1 2016

Hypertension - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hypertension - Pipeline Review, H1 2016
Published Jun 08, 2016
564 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hypertension - Pipeline Review, H1 2016, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypertension
- The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC7972IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents228
  List of Tables254
  List of Figures291
Introduction301
  Global Markets Direct Report Coverage301
Hypertension Overview311
Therapeutics Development322
  Pipeline Products for Hypertension Overview321
  Pipeline Products for Hypertension Comparative Analysis331
Hypertension Therapeutics under Development by Companies349
Hypertension Therapeutics under Investigation by Universities/Institutes432
Hypertension Pipeline Products Glance453
  Late Stage Products451
  Clinical Stage Products461
  Early Stage Products471
Hypertension Products under Development by Companies4813
Hypertension Products under Investigation by Universities/Institutes612
Hypertension Companies Involved in Therapeutics Development63100
  A1M Pharma AB631
  AbbVie Inc.641
  Ache Laboratorios Farmaceuticos S/A651
  Actelion Ltd661
  Afferent Pharmaceuticals, Inc.671
  Allergan Plc681
  Alnylam Pharmaceuticals, Inc.691
  Anacor Pharmaceuticals, Inc.701
  APT Therapeutics, Inc.711
  Arena Pharmaceuticals, Inc.721
  Ascendis Pharma A/S731
  AVEO Pharmaceuticals, Inc.741
  Bayer AG751
  Bial - Portela &Ca, S.A.761
  Bio-inRen771
  BioRestorative Therapies, Inc.781
  Bristol-Myers Squibb Company791
  Cellceutix Corporation801
  Celsion Corporation811
  Celtaxsys, Inc.821
  Chong Kun Dang Pharmaceutical Corp.831
  CJ HealthCare Corp.841
  Complexa, Inc.851
  Conatus Pharmaceuticals Inc.861
  Cytokinetics, Inc.871
  Daewoong Pharmaceutical Co., Ltd.881
  Daiichi Sankyo Company, Limited891
  DiaMedica Inc.901
  Eli Lilly and Company911
  Esperion Therapeutics, Inc.921
  F. Hoffmann-La Roche Ltd.931
  Galectin Therapeutics, Inc.941
  Genextra S.p.a.951
  Gilead Sciences, Inc.961
  GlaxoSmithKline Plc971
  Glenveigh Medical, LLC981
  HanAll Biopharma Co., Ltd.991
  Hanmi Pharmaceuticals, Co. Ltd.1001
  HitGen LTD1011
  Innopharmax Inc.1021
  Insmed Incorporated1031
  INVENT Pharmaceuticals, Inc.1041
  Ionis Pharmaceuticals, Inc.1051
  Jeil Pharmaceutical Co., Ltd.1061
  Johnson &Johnson1071
  JW Pharmaceutical Corporation1081
  Kowa Company, Ltd.1091
  Lee's Pharmaceutical Holdings Limited1101
  Les Laboratoires Servier SAS1111
  LFB S.A.1121
  LG Life Science LTD.1131
  LinXis B.V.1141
  Lotus Pharmaceutical Co., Ltd.1151
  Mallinckrodt Plc1161
  Mast Therapeutics, Inc.1171
  Merck &Co., Inc.1181
  Mezzion Pharma Co. Ltd.1191
  miRagen Therapeutics, Inc.1201
  Mitsubishi Tanabe Pharma Corporation1211
  Morphogen-IX Limited1221
  Neurim Pharmaceuticals Ltd1231
  Nippon Kayaku Co., Ltd.1241
  Nippon Shinyaku Co., Ltd.1251
  Novartis AG1261
  Noxamet Ltd1271
  Omeros Corporation1281
  Ono Pharmaceutical Co., Ltd.1291
  Peloton Therapeutics, Inc.1301
  Pfizer Inc.1311
  PhaseBio Pharmaceuticals, Inc.1321
  Pluristem Therapeutics Inc.1331
  Proteo, Inc.1341
  Pulmokine, Inc.1351
  Quantum Genomics SA1361
  Reata Pharmaceuticals, Inc.1371
  RedHill Biopharma Ltd.1381
  Respira Therapeutics, Inc.1391
  Reviva Pharmaceuticals Inc.1401
  Sanofi1411
  Selten Pharma, Inc1421
  Serodus ASA1431
  Shanghai Pharmaceutical Co., Ltd.1441
  Sihuan Pharmaceutical Holdings Group Ltd.1451
  Silence Therapeutics Plc1461
  Simcere Pharmaceutical Group1471
  SteadyMed Therapeutics, Inc.1481
  Suda Ltd1491
  Sumitomo Dainippon Pharma Co., Ltd.1501
  Takeda Pharmaceutical Company Limited1511
  The Medicines Company1521
  Theravance Biopharma, Inc.1531
  Toray Industries, Inc.1541
  Torrent Pharmaceuticals Limited1551
  TSH Biopharm Corporation Limited1561
  vasopharm GmbH1571
  VBS Pharmaceuticals1581
  Vectura Group Plc1591
  VG Life Sciences, Inc.1601
  Vicore Pharma AB1611
  Yuhan Corporation1621
Hypertension Therapeutics Assessment16320
  Assessment by Monotherapy Products1631
  Assessment by Combination Products1641
  Assessment by Target1658
  Assessment by Mechanism of Action1736
  Assessment by Route of Administration1792
  Assessment by Molecule Type1812
Drug Profiles183382
  (amlodipine + olmesartan medoxomil) - Drug Profile1831
    Product Description1831
    Mechanism of Action1831
    R&D Progress1831
  (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile1841
    Product Description1841
    Mechanism of Action1841
    R&D Progress1841
  (amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile1851
    Product Description1851
    Mechanism of Action1851
    R&D Progress1851
  (amlodipine besylate + candesartan cilexetil) - Drug Profile1861
    Product Description1861
    Mechanism of Action1861
    R&D Progress1861
  (amlodipine besylate + candesartan cilexetil) - Drug Profile1871
    Product Description1871
    Mechanism of Action1871
    R&D Progress1871
  (amlodipine besylate + candesartan cilexetil) - Drug Profile1881
    Product Description1881
    Mechanism of Action1881
    R&D Progress1881
  (amlodipine besylate + celecoxib) - Drug Profile1892
    Product Description1891
    Mechanism of Action1891
    R&D Progress1892
  (amlodipine besylate + indapamide + perindopril) - Drug Profile1911
    Product Description1911
    Mechanism of Action1911
    R&D Progress1911
  (amlodipine besylate + irbesartan) - Drug Profile1921
    Product Description1921
    Mechanism of Action1921
    R&D Progress1921
  (amlodipine besylate + perindopril) - Drug Profile1932
    Product Description1931
    Mechanism of Action1931
    R&D Progress1932
  (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile1951
    Product Description1951
    Mechanism of Action1951
    R&D Progress1951
  (amlodipine besylate + rosuvastatin calcium) - Drug Profile1961
    Product Description1961
    Mechanism of Action1961
    R&D Progress1961
  (amlodipine maleate + chlorthalidone + telmisartan) - Drug Profile1971
    Product Description1971
    Mechanism of Action1971
    R&D Progress1971
  (amlodipine maleate + dextromethorphan hydrobromide) - Drug Profile1981
    Product Description1981
    Mechanism of Action1981
    R&D Progress1981
  (aspirin + lisinopril + lovastatin) - Drug Profile1991
    Product Description1991
    Mechanism of Action1991
    R&D Progress1991
  (atorvastatin calcium + losartan potassium) - Drug Profile2001
    Product Description2001
    Mechanism of Action2001
    R&D Progress2001
  (atorvastatin calcium + perindopril) - Drug Profile2011
    Product Description2011
    Mechanism of Action2011
    R&D Progress2011
  (candesartan cilexetil + metformin hydrochloride) - Drug Profile2021
    Product Description2021
    Mechanism of Action2021
    R&D Progress2021
  (candesartan cilexetil + nifedipine) - Drug Profile2031
    Product Description2031
    Mechanism of Action2031
    R&D Progress2031
  (candesartan cilexetil + rosuvastatin calcium) - Drug Profile2041
    Product Description2041
    Mechanism of Action2041
    R&D Progress2041
  (chlorthalidone + telmisartan) - Drug Profile2051
    Product Description2051
    Mechanism of Action2051
    R&D Progress2051
  (chlorthalidone + valsartan) - Drug Profile2061
    Product Description2061
    Mechanism of Action2061
    R&D Progress2061
  (indapamide + perindopril) - Drug Profile2071
    Product Description2071
    Mechanism of Action2071
    R&D Progress2071
  (lercanidipine hydrochloride + valsartan) - Drug Profile2081
    Product Description2081
    Mechanism of Action2081
    R&D Progress2081
  (levamlodipine + rosuvastatin calcium + telmisartan) - Drug Profile2091
    Product Description2091
    Mechanism of Action2091
    R&D Progress2091
  (nebivolol + valsartan) - Drug Profile2102
    Product Description2101
    Mechanism of Action2101
    R&D Progress2102
  (olmesartan medoxomil + rosuvastatin calcium) - Drug Profile2121
    Product Description2121
    Mechanism of Action2121
    R&D Progress2121
  (pitavastatin + valsartan) - Drug Profile2131
    Product Description2131
    Mechanism of Action2131
    R&D Progress2131
  A-11 - Drug Profile2141
    Product Description2141
    Mechanism of Action2141
    R&D Progress2141
  A1M-001 - Drug Profile2151
    Product Description2151
    Mechanism of Action2151
    R&D Progress2151
  AF-130 - Drug Profile2161
    Product Description2161
    Mechanism of Action2161
    R&D Progress2161

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hypertension - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hypertension-Pipeline-Review-H1-2016-2088-15895>
  
APA:
Global Markets Direct - Market Research. (2016). Hypertension - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hypertension-Pipeline-Review-H1-2016-2088-15895>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.